4Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma[ J]. Eur Respir J, 1995,8(8):1263.
5Monforte V, Roman A, Gavalda J, et al, Nebulized amphotericin B concentration and distribution in the respiratory tract dof lung transplanted patients [ J ]. Transplantation, 2003,75 ( 9 ) : 1571.
6Mann F, Partovi N, Wasan KM, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients[J]. Ann Pharmacother, 2002,36(1):46.
7Koizumi T, Kubo K, Kaneki T, et al. Pharmacokinetic evaluation of amphoteriein B in lung tissue: lung lymph distribution after aerosolization and inhalation of amphotericin B [ J ]. Antimicrob Agents Chemother, 1998,42(7) : 1597.
3LU B. New Techniques and New Dosage Forms of Drugs (药物新剂型与新技术)[M].2nd ed. Beijing: People' s Medical Publishing House,2005:370-463.
4CUI F D. Pharmaceutics(药剂学)[M].6th ed. Beijing: People's Medical Publishing House,2007:420-448.
5XIALF.Drug adverse reaction of eye drop.首都医药,2007,4:39-40.
6Sarosi GA. Amphotericin B:still the ‘gold standard' for antifungal therapy[J]. Postgrad Med, 1990, 88: 151-152, 155-156, 165-166
7Grasela TH Jr, Goodwin SD, Walawander MK, et al. Prospective surveillance of intravenous amphotericin B use patterns[J]. Pharmacotherapy, 1990,10: 341-348
8Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects[J]. Clin Infect Dis,1998, 26: 334-338
9Luber AD, Maa L, Lam M, et al. Risk factors for amphotericin B-induced nephrotoxicity[J]. J Antimicrob Chemoth,1999, 43: 267-271
8Konizumi T, Kubo K, Kaneki T, et al. Pharmacokinetic evaluation of amphotericiu B in lung tissue : lung lymph distribution after aerosolization and inhalation of amphotericin B[J]. Antimicrob Agents Cbemother, 1998, 42(7) : 1597.
9Monforte V, Roman A, Gavald6 J, et al. Nebulized amphoterlein B concentration and distribution in the respiratory tract of lung transplanted patients[J]. Transplantation, 2003, 75(9): 1571.
